ClinicalTrials.gg
RecruitingNCT06741644Updated Aug 20, 2026

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

A Phase 1/2 interventional study of CS2009 and CS2009 in Advanced Solid Tumors, sponsored by CStone Pharmaceuticals. Recruiting at 33 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by CStone Pharmaceuticals · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
800
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy in Participants with Advanced Solid Tumors. The study is comprised of a Phase I dose escalation and Phase II dose expansion.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • PD-1
  • VEGFA
  • CTLA4
  • tri-specific antibody
  • advanced solid tumors
  • Phase I
03

In context

Lead sponsor

CStone Pharmaceuticals is the lead sponsor of 29 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Evidence of a personally signed and dated document.
  • Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Age ≥ 18 years on the day of signing informed consent.

Phase I:

  • or cytologically confirmed, unresectable advanced solid tumors, including but not limited to non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), gastric cancer (GC), ovarian cancer (OC), cervical cancer (CC), etc.
  • Failure of established standard of care for advanced disease, or no available standard of care.

Phase II:

  • Pathologically or cytologically confirmed unresectable advanced solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), etc.
  • Participants with at least one as defined per v1.1 solid tumor.
  • (ECOG) performance status of 0 or 1.
  • Adequate organ function.
  • Fertile male participants and female participants of must be willing to use an effective method of from providing signed consent and for 180 days after the last product administration.
  • Female participants of childbearing potential must have a negative pregnancy test ≤ 7 days prior to the first dose of the investigational product.

Exclusion criteria

Exclusion Criteria:

  • History of a second active within the previous 3 years except for locally curable cancers that have been apparently cured.
  • Known primary central nervous system (CNS) tumor or solid tumor that is either symptomatic, untreated, or requires therapy.
  • Presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage within 4 weeks prior to the first dose of product.
  • Receipt of systemic treatment or any other form of immune suppressing treatment within 7 days prior to the first dose of investigational product.
  • Active or prior history of definite inflammatory bowel disease.
  • History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, or presence of active or suspected ILD/pneumonitis.
  • Active infections requiring systemic therapy within 2 weeks prior to the first dose of investigational product.
  • Positive for (HIV) or presence of acquired immune deficiency syndrome (AIDS).
  • Active or C infection.
  • Active pulmonary tuberculosis (TB).
  • Major surgery, chemotherapy, definitive radiotherapy, target therapy, immunotherapy, or other anti-cancer therapy within 21 days prior to the first dose of investigational product.
  • Palliative radiotherapy within 14 days prior to the first dose of investigational product, or receipt of radioactive drug within 56 days prior to the first dose of investigational product.
  • Administration of within 28 days prior to the first dose of investigational product.
  • History of allogeneic organ transplantation and hematopoietic stem cell transplantation.
  • Receipt of antitumor Chinese herbal preparations or Chinese patent medicine within 7 days prior to the first dose of investigational product.
  • Receipt of any other investigational drugs within 21 days prior to the first dose in this trial.
  • History of or idiosyncrasy to the of the study drug or any monoclonal antibody.
  • Any toxic effects of prior therapy or surgical procedures unresolved to baseline severity or Version 5.0 Grade ≤ 1.
  • Active alcohol or drug abuse.
  • Female participants who are pregnant or breastfeeding.
  • Other acute or chronic medical or psychiatric conditions that may increase the risk associated with study participation or investigational product administration.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    Participants will be administered escalating doses of CS2009.

    Drug: CS2009

  • Experimental
    Dose Expansion

    Participants will be administered the recommended dose(s) of CS2009 with or without chemotherapy according to dose-escalation data.

    Drug: CS2009 · Drug: Pemetrexed · Drug: Carboplatin · Drug: Paclitaxel · Drug: Etoposide · Drug: Nab-paclitaxel · Drug: Oxaliplatin · Drug: Capecitabine · Drug: Docetaxel · Drug: Leucovorin · Drug: 5-FU · Drug: Cisplatin · Drug: Gemcitabine · Drug: Irinotecan

Interventions

06

What researchers measure

Primary outcomes

  1. [Dose Escalation] Maximum tolerated dose (MTD) of CS2009

    Participants will receive CS2009 via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). The MTD will be determined, if any, by the number of participants who experience a dose limiting toxicity (DLT).

    Time frame: Cycle 1 (Up to 21 Days)

  2. [Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS2009

    The selection of tentative RP2D will be based on consideration of overall safety information together with available pharmacokinetic, pharmacodynamic, and efficacy data. The tentative RP2D may be the MTD or a lower dose within the tolerable dose range.

    Time frame: Cycle 1 (Up to 21 Days)

  3. [Dose Escalation] Number of participants with adverse events (AEs)

    Time frame: Up to approximately 2 years

  4. [Dose Expansion] Objective response rate (ORR) evaluated by investigators per RECIST v1.1

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. [Dose Escalation & Expansion] Area under the curve (AUC) of CS2009

    Time frame: Up to approximately 2 years

  2. [Dose Escalation & Expansion] Maximum concentration (Cmax) of CS2009

    Time frame: Up to approximately 2 years

  3. [Dose Escalation & Expansion] Elimination half-life (t1/2) of CS2009

    Time frame: Up to approximately 2 years

  4. [Dose Escalation & Expansion] Minimum concentration (Cmin) of CS2009

    Time frame: Up to approximately 2 years

  5. [Dose Escalation & Expansion] Number of participants with anti-CS2009 antibodies

    Time frame: Up to approximately 2 years

  6. [Dose Escalation] Objective response rate (ORR) evaluated by investigators per RECIST v1.1

    Time frame: Up to approximately 2 years

  7. [Dose Expansion] Number of participants with adverse events (AEs)

    Time frame: Up to approximately 2 years

07

Study locations

32 of 33 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Jan 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2024
First posted
Dec 19, 2024
StartActual
Feb 24, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2028
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06741644
Responsible party
Sponsor
First posted
Dec 19, 2024
Start date
Feb 24, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Aug 20, 2026

Study contacts

Jingru Wang
Contact
wangjingru@cstonepharma.com
+86 18017113282

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion